• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。

Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.

出版信息

Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.

DOI:10.3201/eid2310.170303
PMID:28758889
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5621552/
Abstract

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

摘要

我们描述了 27 名年龄<18 岁的儿童和青少年，他们在接受耐多药结核病治疗时接受了贝达喹啉。我们报告了良好的治疗反应，没有因不良反应而停药。当治疗选择有限时，贝达喹啉可考虑用于该年龄组的耐多药结核病。

相似文献

1
Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.贝达喹啉在儿童和青少年耐多药结核病中的超说明书使用。
Emerg Infect Dis. 2017 Oct;23(10):1711-3. doi: 10.3201/eid2310.170303. Epub 2017 Oct 17.
2
Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.美国疾病预防控制中心（CDC）临时使用和安全监测苯并恶嗪盐酸盐（Sirturo）治疗耐多药结核病的指南。
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12.
3
Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.贝达喹啉：一种用于治疗耐多药结核病的新型抗结核药物。
Pharmacotherapy. 2014 Nov;34(11):1187-97. doi: 10.1002/phar.1482. Epub 2014 Sep 9.
4
The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.使用贝达喹啉治疗耐多药结核病和终末期肾病患者：一例报告。
Int J Infect Dis. 2018 Nov;76:88-90. doi: 10.1016/j.ijid.2018.09.009. Epub 2018 Sep 19.
5
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.抗结核药物贝达喹啉引入政策的权衡：基于模型的分析
PLoS Med. 2016 Oct 11;13(10):e1002142. doi: 10.1371/journal.pmed.1002142. eCollection 2016 Oct.
6
Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.贝达喹啉治疗耐多药和广泛耐药结核病。
Eur Respir J. 2016 Feb;47(2):564-74. doi: 10.1183/13993003.00724-2015. Epub 2015 Dec 2.
7
Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis.贝达喹啉：一种用于耐多药结核病的新型二芳基喹啉。
Ann Pharmacother. 2014 Jan;48(1):107-15. doi: 10.1177/1060028013504087. Epub 2013 Nov 1.
8
Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.耐多药结核病患者延长使用贝达喹啉治疗的长期结局和安全性。
Eur Respir J. 2017 Mar 22;49(3). doi: 10.1183/13993003.01799-2016. Print 2017 Mar.
9
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis.贝达喹啉和德拉马尼联合治疗 5 例广泛耐药肺结核患者。
Emerg Infect Dis. 2017 Oct;23(10):1718-21. doi: 10.3201/eid2310.170834. Epub 2017 Oct 17.
10
▼Bedaquiline for multidrug-resistant tuberculosis.▼贝达喹啉用于耐多药结核病。
Drug Ther Bull. 2014 Nov;52(11):129-32. doi: 10.1136/dtb.2014.11.0291.

引用本文的文献

1
Treatment outcomes of bedaquiline-based longer oral antitubercular regimens in Indian children above five years of age.基于贝达喹啉的更长疗程口服抗结核方案在印度5岁以上儿童中的治疗效果。
Lung India. 2025 Jul 1;42(4):330-336. doi: 10.4103/lungindia.lungindia_609_24. Epub 2025 Jun 27.
2
Efficacy and safety of bedaquiline containing regimens in patients of drug-resistant tuberculosis: An updated systematic review and meta-analysis.含贝达喹啉方案治疗耐多药结核病患者的疗效和安全性：一项更新的系统评价和荟萃分析。
J Clin Tuberc Other Mycobact Dis. 2023 Dec 1;34:100405. doi: 10.1016/j.jctube.2023.100405. eCollection 2024 Feb.
3
Favourable outcomes in RR-TB patients using BPaL and other WHO-recommended second-line anti-TB drugs.使用 BPaL 和其他世行推荐的二线抗结核药物治疗 RR-TB 患者的有利结局。
Int J Tuberc Lung Dis. 2023 Aug 1;27(8):599-605. doi: 10.5588/ijtld.22.0649.
4
Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children.新药贝达喹啉和德拉马尼在儿童耐多药结核病治疗中的进展。
Front Cell Infect Microbiol. 2023 Jun 13;13:1183597. doi: 10.3389/fcimb.2023.1183597. eCollection 2023.
5
Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis.贝达喹啉方案与耐多药结核病：系统评价和荟萃分析。
J Bras Pneumol. 2022 May 30;48(2):e20210384. doi: 10.36416/1806-3756/e20210384. eCollection 2022.
6
Treatment of Rifampicin-Resistant Tuberculosis Disease and Infection in Children: Key Updates, Challenges and Opportunities.儿童耐利福平结核病的治疗与感染：重要进展、挑战与机遇
Pathogens. 2022 Mar 23;11(4):381. doi: 10.3390/pathogens11040381.
7
Bedaquiline for multidrug-resistant TB in paediatric patients.贝达喹啉治疗儿童耐多药结核病。
Int J Tuberc Lung Dis. 2021 Sep 1;25(9):716-724. doi: 10.5588/ijtld.21.0022.
8
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid.儿童耐多药和广泛耐药结核病的治疗：贝达喹啉和德拉马尼的作用
Microorganisms. 2021 May 17;9(5):1074. doi: 10.3390/microorganisms9051074.
9
Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains.初治结核分枝杆菌临床菌株中与对贝达喹啉和地拉曼迪耐药相关的基因组变异特征分析
J Clin Microbiol. 2020 Oct 21;58(11). doi: 10.1128/JCM.01304-20.
10
Investigation of genus as a new source of antimycobaterial agents.将属作为抗真菌药物新来源的研究。 （注：原文中“antimycobaterial”有误，推测应为“antimycobacterial”，意为“抗分枝杆菌的”，但按照指令要求未作修改直接翻译，这里译文与原文对应，若修正错误单词后译文为“将属作为抗分枝杆菌药物新来源的研究” ）
Future Sci OA. 2020 May 29;6(7):FSO587. doi: 10.2144/fsoa-2020-0018.

本文引用的文献

1
New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.新型和再利用药物治疗儿童耐多药结核病。基于实践的建议。
Am J Respir Crit Care Med. 2017 May 15;195(10):1300-1310. doi: 10.1164/rccm.201606-1227CI.
2
Global burden of drug-resistant tuberculosis in children: a mathematical modelling study.全球儿童耐多药结核病负担：一项数学建模研究。
Lancet Infect Dis. 2016 Oct;16(10):1193-1201. doi: 10.1016/S1473-3099(16)30132-3. Epub 2016 Jun 21.
3
Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges.儿童和青少年耐多药和广泛耐药结核病新药的同情使用：早期经验和挑战。
Eur Respir J. 2016 Sep;48(3):938-43. doi: 10.1183/13993003.00705-2016. Epub 2016 Jun 23.
4
Identification of patients who could benefit from bedaquiline or delamanid: a multisite MDR-TB cohort study.识别可能从贝达喹啉或地拉马尼中获益的患者：一项多中心耐多药结核病队列研究。
Int J Tuberc Lung Dis. 2016 Feb;20(2):177-86. doi: 10.5588/ijtld.15.0962.
5
Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates.儿童耐多药结核病发病情况：系统评价和全球估计。
Lancet. 2014 May 3;383(9928):1572-9. doi: 10.1016/S0140-6736(14)60195-1. Epub 2014 Mar 24.
6
Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.美国疾病预防控制中心（CDC）临时使用和安全监测苯并恶嗪盐酸盐（Sirturo）治疗耐多药结核病的指南。
MMWR Recomm Rep. 2013 Oct 25;62(RR-09):1-12.
7
High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.儿童耐多药结核病治疗成功率高：一项观察性队列研究。
Thorax. 2014 May;69(5):458-64. doi: 10.1136/thoraxjnl-2013-203900. Epub 2013 Sep 24.
8
Hearing loss in children treated for multidrug-resistant tuberculosis.儿童耐多药结核病治疗后的听力损失。
J Infect. 2013 Apr;66(4):320-9. doi: 10.1016/j.jinf.2012.09.002. Epub 2012 Sep 6.